Quarterly Earnings

Asana reports Q2 results on Sept. 3, putting its bold 'human-agent teams' strategy to the test. All eyes are on whether its AI vision is driving growth.

Beyond strong Q2 earnings, Vertex's 'AI-First' push is reshaping tax tech. The firm raises its outlook, citing AI efficiency and global e-invoicing demand.

Ichor Holdings posts impressive Q2 growth, signaling a wider industry rebound. A $200M capital raise and disciplined strategy position it for the next tech supercycle.

Beyond record profits, Advanced Energy's Q2 results show how foundational tech, not just algorithms, is fueling the AI and data center explosions.

As ProMIS Neurosciences preps its Q2 update, all eyes are on its lead Alzheimer's drug. Can its "sniper-like" precision deliver efficacy without the side effects plaguing the field?

Strong performance from its Industrial Equipment division, boosted by a key acquisition, helps Alamo Group navigate mixed market conditions and post solid Q2 results.

Michigan's Oxford Bank posts a strong Q2 rebound driven by niche lending, but rising nonperforming assets and a strategic funding shift reveal a complex path to profit.

QHSLab flips to Q2 profit, driven by a recurring revenue model that's reshaping primary care. Is its strategic debt cleanup the key to sustainable growth?

Cohen & Company's Q2 results showcase its mastery of the resurgent SPAC market. With revenue soaring to $69.5M and major deals inked, the boutique firm proves that specialized expertise can deliver outsized returns.

As Sonida Senior Living prepares its Q2 results, investors are watching closely. Can the operator prove its massive merger is paying off amidst industry-wide cost pressures?

With blockbuster sales for its MS drug BRIUMVI, TG Therapeutics is raising revenue targets and aggressively expanding its pipeline into new diseases.

Riding a wave of strong Q2 results, Supernus announces a merger of equals with Indivior, set to create a new, scaled player in CNS and addiction medicine.

With its AI platform generating novel targets, Compugen advances a key ovarian cancer drug while partners AstraZeneca and Gilead push its discoveries forward.

As DarioHealth prepares its Q2 results, investors are watching closely. Can its disciplined cost-cutting and AI-powered platform deliver on the promise of profitability?

CNA Financial's Q2 results show rising net income, but a closer look reveals declining underwriting profits are being offset by strong investment returns.

Japan's largest bank reports a stunning 48% profit jump, fueled by higher domestic loan margins and its Morgan Stanley stake, beating analyst estimates.

Pathward Financial's stock plunged after its 'green' energy loans soured, sparking a fraud probe. Is this a cautionary tale for the entire ESG movement?

The regional bank posted a 50% jump in Q2 profits, but a deeper dive reveals a troubling surge in problem loans, posing a critical test for its growth strategy.

The community bank's record-setting profitability and dividend hike signal strength, yet declining deposits and rising troubled loans tell a complex story.

TWC Enterprises reported lower Q2 earnings, but the real story isn't the 9% drop in golf rounds. It's the company's growing reliance on volatile real estate and stock market gains.